Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,428
  • Shares Outstanding, K 15,083
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,130 K
  • 60-Month Beta 2.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade REVB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings -0.47 on 05/16/22
  • Next Earnings Date 08/15/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4036 +55.03%
on 06/01/22
0.7890 -20.70%
on 06/29/22
+0.0936 (+17.59%)
since 05/27/22
3-Month
0.4036 +55.03%
on 06/01/22
1.4900 -58.01%
on 04/21/22
-1.5143 (-70.76%)
since 03/29/22
52-Week
0.4036 +55.03%
on 06/01/22
11.2900 -94.46%
on 01/05/22
-9.4043 (-93.76%)
since 06/29/21

Most Recent Stories

More News
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

-Data anticipated in Q3 2022-...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update

-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE)...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...

ONCY : 1.0042 (+1.18%)
ONC.TO : 1.31 (+0.77%)
SPPI : 0.8030 (-5.51%)
LBPS : 1.6500 (+2.48%)
REVB : 0.6257 (+27.05%)
CELZ : 0.6944 (+1.55%)
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
Revelation Biosciences Raises $7.76 Million in Equity Financing

SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0538 (+12.55%)
REVB : 0.6257 (+27.05%)
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro...

REVB : 0.6257 (+27.05%)
REVBW : 0.0538 (+12.55%)
Sandy Spring Bancorp, Inc. and Revere Bank Receive Shareholder Approval for Merger

OLNEY, Md., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Sandy Spring Bancorp, Inc. (NASDAQ: SASR, “Sandy Spring”) and Revere Bank (OTCQX: REVB, “Revere”) jointly announced that the companies have received...

SASR : 39.18 (-0.91%)
REVB : 0.6257 (+27.05%)
Revere Bank Announces Record Earnings for 2019 – Net Income of $31.70 Million Increased 14.7% Over 2018's Record Earnings

ROCKVILLE, Md., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Revere Bank (the “Bank”) (OTCQX: REVB) today reported quarterly net income of $8.04 million for the quarter ended December 31, 2019, an 11.4% increase...

REVB : 0.6257 (+27.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra...

See More

Key Turning Points

3rd Resistance Point 1.0748
2nd Resistance Point 0.9319
1st Resistance Point 0.7788
Last Price 0.6257
1st Support Level 0.4828
2nd Support Level 0.3399
3rd Support Level 0.1868

See More

52-Week High 11.2900
Fibonacci 61.8% 7.1314
Fibonacci 50% 5.8468
Fibonacci 38.2% 4.5622
Last Price 0.6257
52-Week Low 0.4036

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar